Nicox SA is primarily active in the pharmaceutical industry.

The main competitors of Nicox SA in the market include pharmaceutical companies such as Allergan, Bausch Health Companies, and Santen Pharmaceutical.

Nicox SA, a renowned pharmaceutical corporation, has an extensive history and background. Founded in 1996, Nicox SA focuses on research and development in the ophthalmic field. The company is headquartered in France and specializes in the development of innovative therapeutic solutions for various ocular conditions. With a strong commitment to advancing patient care, Nicox SA leverages its expertise in nitric oxide-donating technology to create differentiated products. It has a diverse and talented team of professionals dedicated to improving eye health worldwide. Nicox SA continues to strive towards breakthroughs in ophthalmology, aiming to enhance treatments and redefine standards of care in the industry.

Nicox SA has achieved several significant milestones throughout its history. One notable achievement includes the successful development and commercialization of its innovative ophthalmic products, such as VYZULTA® and ZERVIATE®. Additionally, the company has made advancements in its research pipeline, with promising candidates targeting various ophthalmic conditions. Nicox SA has also formed strategic partnerships with well-established pharmaceutical companies, enhancing its global reach and market presence. The company's commitment to continuous innovation and strategic collaborations has propelled its growth and positioned it as a key player in the ophthalmic industry.

Nicox SA is primarily present in various countries and regions across the globe. Its presence spans across Europe, particularly in France where the company is headquartered. Additionally, Nicox SA has established its presence in the United States, focusing on the significant pharmaceutical market there. The company's operations and reach also extend to other countries in Europe, including Germany, Spain, Italy, and the United Kingdom, as well as parts of Asia and the Middle East. With its widespread global presence, Nicox SA aims to serve a diverse range of markets and customers, contributing to its overall growth and success.

Nicox SA is a pharmaceutical company committed to improving patients' lives through innovative solutions. The company's core values include integrity, excellence, and collaboration. Nicox SA believes in putting patients first and strives to deliver high-quality products that meet their needs. With a focus on ophthalmology, Nicox SA aims to revolutionize eye care by developing novel therapies and diagnostic tools. Their corporate philosophy values scientific expertise, ethical conduct, and a passion for innovation. By combining cutting-edge research with a patient-centric approach, Nicox SA aims to make a significant impact on the ophthalmic pharmaceutical industry.

Analysts currently set an average price target of 1,53 EUR for the Nicox stock (median: 1,53 EUR), implying +295,9 % versus the latest price. The consensus is based on 9 analyst ratings.

Nicox Analyytikkojen kursstavoitteet 2026

9 analysts currently rate the Nicox stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Nicox to generate revenue of 3,00 M EUR and earnings per share of −0,09 EUR.

Nicox Analyytikkojen kursstavoitteet 2026

The Nicox share (ALCOX.PA) is listed on 7 stock exchanges, including: Frankfurt (NXOA.F), München (NXOA.MU), Düsseldorf (NXOA.DU), London (0RCQ.L), Paris (COX.PA).

Nicox SA is a pharmaceutical company specializing in the development, manufacture, and marketing of innovative drugs for eye diseases. The company was founded in 1996 and is headquartered in Sophia-Antipolis, France. The business model of Nicox SA is based on the development and marketing of eye medications. The company conducts research and development in three main areas: glaucomatous eye diseases, inflammatory diseases of the eye, and retinal diseases. Nicox SA is currently focused on developing products for the treatment of glaucoma and dry eye. Nicox SA's research and development activities focus on its Nitric Oxide-donating Technology (NOCs), which aims to develop drugs that target the specific causes and symptoms of eye diseases. The NOCs technology is a patented process that allows for optimal use of active ingredients in clinical trials and marketing. Nicox SA has a portfolio of products that are already on the market and licensed by various companies. These include AdenoPlus, a diagnostic platform for detecting adenovirus conjunctivitis, Vyzulta, a prostaglandin analogue for the treatment of glaucoma, and Zerviate, an antihistamine for the treatment of seasonal allergic conjunctivitis. Nicox SA maintains partnerships with various companies to market and further develop its products worldwide. These include Bausch + Lomb, an optical products company, and Ocumension, a Chinese ophthalmic medication company. Through these alliances, Nicox SA will be able to expand its reach and distribution channels. In 2020, Nicox SA obtained market approval for Vyzulta in several US states and in Europe. It is currently the first product based on the NOCs technology to be approved for the treatment of glaucoma. The company currently plans to develop additional drugs based on its NOCs technology for the treatment of glaucoma and dry eye. These drugs are expected to be distinguished by their effectiveness, safety, and tolerability. Overall, Nicox SA is a pharmaceutical company specializing in the development and marketing of innovative drugs for eye diseases. The company relies on its NOCs technology to develop and market targeted active ingredients for specific eye diseases. With strong partnerships and a growing product pipeline, Nicox SA aims to improve the quality of life for patients with eye diseases worldwide.

odotettu liikevaihto Nicox on 3,00 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Nicox on −6,19 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Nicox:n hinta-voitto-suhde (P/E) on tällä hetkellä −4,31. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Nicox-osakkeen arvostusta.

Nicox:n hinta-myynti-suhde (P/S) on tällä hetkellä 8,89. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Nicox-osakkeen arvostuskennuslukuna.

Nicox:n Eulpool-laatuscore on 2/10.

Nicox:n ISIN on FR0013018124. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Nicox:n WKN on A143G8. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Nicox:n ticker on ALCOX.PA. Tämä pörssinoteeraus käytetään Nicox-osakkeiden kauppaan pörssissä.

Nicox maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Nicox kuuluu sektoriin 'Terveydenhuolto'.

Nicox:n osingot jaetaan valuutassa EUR.